for existing 1st-line treatment are not well understood in Europe.

**Methodology** Endometrial Cancer Health Outcomes-Europe-1st-Line (ECHO-EU-1L) is a multicenter, retrospective, chart review study in patients diagnosed with recurrent or aEC across the United Kingdom (UK), France, Germany, Italy, and Spain. Physicians extracted data from medical records of adult female patients diagnosed with recurrent or aEC (Stage III or IV) initiating 1st-line systemic therapy between July 1, 2016 – March 31, 2020. Data included patient demographics, clinical/treatment characteristics, and clinical outcomes. Data were de-identified before conducting analyses. Kaplan-Meier analyses were performed to estimate time-to-treatment discontinuation, real-world progression-free survival (rwPFS) and overall survival (OS). The study was IRB-approved in respective countries.

**Results** At 1st-line initiation, median age of 244 eligible patients was 69 years, 49.6% had endometroid carcinoma histology, and 76.7% had an ECOG status of 0/1. For 1st-line therapy, 227 (93%) received chemotherapy-based regimen (carboplatin plus paclitaxel (CP) most common), while 7% received hormonal or other therapy. After a median of 3 months on 1st-line therapy, 163 (66.8%) patients reached an overall response; 70 (43%) eventually lost response. During the 19-month median follow-up, 233 (96%) discontinued after a median of 3 months. Median OS from 1st-line initiation was 21 months (95% CI:18.0–23.0) and median rwPFS was 12 months (95% CI:11.0–14.0).

**Conclusion** In Europe, CP is the standard 1st treatment for recurrent or aEC patients. A third of patients do not respond to CP therapy; patients had poor outcomes with median survival <2 years and median PFS of 1 year. Overall, there seems to be significant unmet medical need and novel therapies could improve outcomes in this patient population.

**Introduction/Background** Recently approved therapies have proven clinical benefits for recurrent or advanced endometrial cancer (aEC) patients with known microsatellite instability (MSI) status, highlighting the prognostic significance of this biomarker. There is little information available on the prevalence of MSI/mismatch repair (MMR) testing in Europe. The objective of this study was to understand the real-world use of MSI/MMR testing in Europe.

**Methodology** Endometrial Cancer Health Outcomes-Europe-1st-Line (ECHO-EU-5–1L) is a multicenter, retrospective, chart review study conducted in the United Kingdom (UK), France, Germany, Italy, and Spain. Physicians extracted data from medical records of female patients (>18 years-old) diagnosed with recurrent or aEC (Stage III or IV) initiating 1st-line systemic therapy between July 1, 2016 – March 31, 2020. Data included patient demographics, MSI/MMR tumor status, and clinical/treatment characteristics. Data were de-identified before analyses. The study was IRB-approved in respective countries.

**Results** Of the 57 participating physicians, 94.7% were medical oncologists, 56% were in practice for ≥15 years, 96.5% practiced in urban settings, and 91.2% had hospital-based practices. The median age of 244 patients with recurrent or aEC at 1st-line therapy initiation was 69 years, 184 (75%) were White/Caucasian, and 121 (49.6%) had endometrioid carcinoma histology. A total of 88 patients (36.1%) underwent testing to determine MSI/MMR status. Prevalence of testing was 64%, 44%, 29%, 22%, and 20% in Spain, France, Germany, Italy, and the UK, respectively. Of those patients tested, 72 (81.8%) had non-MSI-high/MMR-proficient (pMMR) tumors, 13 (14.8%) had MSI-high/MMR-deficient (dMMR) tumors, and 3 (3.4%) had mixed results (table 1).